Suvorexant

Suvorexant is an aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia. Among its listed roles, it functions as a central nervous system depressant and an orexin receptor antagonist. It belongs to the class of 1,3-benzoxazoles, a member of triazoles, a diazepine, an aromatic amide and an organochlorine compound. Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has received approval for the treatment of insomnia. It is grouped under the following drug class(es): Hypnotics, Psychotropic agents, Schedule IV controlled substances and Sedatives. Its therapeutic use is listed as sleeping drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Methanone, [(7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-Methyl-1H-1, 4-diazepin-1-yl][5-Methyl-2-(2H-1, 2, 3-triazol-2-yl)phenyl]- and suvorexantum. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 24965990.